| Literature DB >> 11357234 |
Abstract
Botulinum A toxin is recognized and approved for symptomatic treatment of hemifacial spasm and blepharospasm. The state of trials is good, although double-blind placebo-controlled studies have been carried out involving only a small number of cases. Open case control studies have been done with large patient collectives. In both indications, treatment with botulinum toxin reaches the highest EBM degree in a critical evaluation.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11357234 DOI： 10.1007/pl00007813
Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849